Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APX-343A
- Development stage
- Phase 1
- Lead developer
- Aptabio Therapeutics
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Oral
01
Overview
APX-343A is an investigational anticancer immunotherapy drug developed by AptaBio Therapeutics. It targets cancer-associated fibroblasts (CAFs) within the tumor microenvironment and is designed to modulate oxidative stress, thereby regulating CAFs to enhance antitumor immune responses and inhibit tumor development and metastasis. This novel mechanism aims to overcome challenges such as low response rates and resistance seen with current immunotherapies. APX-343A is classified as a new molecular entity and is currently in Phase I clinical trials for the treatment of solid tumors[1][2][3][4].
02
Targets
NOX2 (NADPH oxidase 2)NOX4 (NADPH oxidase 4)
Beyond the preview
Go deeper on APX-343A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APX-343A.